GCP
TRAW icon

GSA Capital Partners’s Traws Pharma TRAW Stock Holding History

GSA Capital Partners’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,312
Closed -$147K – 1909
2021
Q4 		$147K Sell
2,312
-7,314
-76% -$588K 0.02% 1276
2021
Q3 		$922K Buy
+9,626
New +$1.24M 0.09% 342
2021
Q1 		– Sell
-608
Closed -$106K – 1550
2020
Q4 		$106K Buy
+608
New +$70.6K 0.02% 1092

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GSA Capital Partners's TRAW Position: Q1 2022 in Review

GSA Capital Partners sold out of Traws Pharma (TRAW) in Q1 2022, closing a stake of 2,312 shares — an estimated $147K sold.

GSA Capital Partners first reported a position in TRAW in Q4 2020 and held it in 3 quarters. The position peaked at $922K in Q3 2021. 30 funds tracked by Wall St. Rank hold TRAW as of Q1 2022.

  • GSA Capital Partners reported no remaining Traws Pharma position as of Q1 2022 after selling out during the quarter.
  • GSA Capital Partners sold 2,312 Traws Pharma shares in Q1 2022, an estimated $147K.
  • GSA Capital Partners first reported a position in Traws Pharma in Q4 2020 and held it in 3 quarters.
  • GSA Capital Partners's Traws Pharma position peaked at $922K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.